Close Menu

NEW YORK (GenomeWeb News) – The Broad Institute of MIT and Harvard has bought 22 new Genome Analyzers, nearly doubling its stock of the Illumina-made sequencers, the company said today.

Broad conducts a wide range of biomedical genomics projects, and has worked in a partnership with the San Diego-based life sciences company. Before this purchase, Broad already had 25 of the analyzers in its tool shed, the company said.

In the coming year, Illumina said that it plans to increase the throughput of the analyzer to as much as 95 gigabases of DNA sequence data per run.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

Jul
23
Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.